Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study.
10.3802/jgo.2011.22.3.188
- Author:
In Ho LEE
1
;
Chel Hun CHOI
;
Dae Gy HONG
;
Jae Yun SONG
;
Young Jae KIM
;
Kyung Tai KIM
;
Kyu Wan LEE
;
Il Soo PARK
;
Duk Soo BAE
;
Tae Jin KIM
Author Information
1. Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Korea. kimonc@hotmail.com
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Clinical study;
Granulosa cell tumor;
Ovary;
Pregnancy;
Recurrence
- MeSH:
Adult;
Chemotherapy, Adjuvant;
Disease-Free Survival;
Female;
Fertility;
Follow-Up Studies;
Granulosa Cell Tumor;
Granulosa Cells;
Humans;
Medical Records;
Multivariate Analysis;
Ovary;
Pregnancy;
Premenopause;
Recurrence;
Retrospective Studies
- From:Journal of Gynecologic Oncology
2011;22(3):188-195
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the clinicopathologic characteristics and prognostic factors of ovarian granulosa cell tumors. METHODS: Medical records of 113 patients presenting between January 1995 and December 2007 were retrospectively reviewed. RESULTS: One-hundred two patients had adult type disease, with a mean age of 46.2 years (range, 18 to 83 years) and a mean follow-up period of 54.7 months (range, 1 to 155 months). The distribution of FIGO stages was 86 patients at stage I, 11 at stage II, and 5 at stage III. During follow-up, ten patients recurred at a mean time of 48 months (range, 4 to 109 months). Among them, three patients died after a mean of 57 months (range, 25 to 103 months). In recurrence analysis, advanced stage (p=0.032) and presence of residual disease (p=0.012) were statistically significant, and age<40 years, premenopause and positive washing cytology were marginally significant (p<0.1). In multivariate analysis, stage was the only factor associated with recurrence; adjuvant chemotherapy and fertility-sparing surgery were not statistically significant. Among 36 patients with fertility-sparing operations, eight patients had nine pregnancies and delivered seven babies. Eleven patients had juvenile type tumors; the mean age was 20.0 years (range, 8 to 45 years) and the mean follow-up period was 69.8 months (range, 20 to 156 months). The distribution of FIGO stage was nine patients at stage I and two at stage III. There were no recurrences or deaths reported. Four patients had seven pregnancies and delivered six babies. CONCLUSION: Stage is the only factor associated with disease-free survival, and fertility-sparing surgery may be a treatment option for women with early-stage disease who want to retain fertility.
